Results 21 to 30 of about 228,187 (396)
Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations.
PLoS ONE, 2021 BackgroundNo medical treatment has proven efficacy for acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF), and this syndrome has a very high mortality.
Tejaswini Kulkarni +10 more
doaj +1 more source
Rheumatology, 2020 Objectives In order to address the reliability of commercial assays to identify myositis-specific and -associated autoantibodies, we aimed to compare the results of two commercial immunoassays with the results obtained by protein immunoprecipitation ...
S. Tansley +3 more
semanticscholar +1 more source
Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management
Frontiers in Neurology, 2020 Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction, characterized by skeletal muscle weakness and fatigability.
K. Lazaridis, S. Tzartos
semanticscholar +1 more source
Comparison of clinical and laboratory characteristics in children with type 1 diabetes according to pancreatic autoantibodies [PDF]
Korean Journal of Pediatrics, 2010 Purpose:The purpose of this study was to determine whether there is any difference in the clinical and laboratory characteristics of patients with autoantibody-positive and patients with autoantibody-negative type 1 diabetes at initial presentation ...
Ji Hae Choi +4 more
doaj +1 more source
Global Journal of Transfusion Medicine, 2018 Background: Autoimmune hemolytic anemia (AIHA) is an immunological disease caused by autoantibodies. Warm autoantibody mainly includes anti-IgG and anti-(IgG+C3d) type, which can cause direct antiglobulin test (DAT) positive.
He Ziyi, Hu Yingming, Cui Siping
doaj +1 more source
Journal of Cachexia, Sarcopenia and Muscle, 2021 Background Nuclear receptor interaction protein (NRIP) co‐localizes with acetylcholine receptor (AChR) at the neuromuscular junction (NMJ), and NRIP deficiency causes aberrant NMJ architecture.
Li‐Kai Tsai +10 more
doaj +1 more source
Autoantibody Discovery, Assay Development and Adoption: Death Valley, the Sea of Survival and Beyond
Frontiers in Immunology, 2021 Dating to the discovery of the Lupus Erythematosus (LE) cell in 1948, there has been a dramatic growth in the discovery of unique autoantibodies and their cognate targets, all of which has led to the availability and use of autoantibody testing for a ...
Marvin J. Fritzler +3 more
doaj +1 more source
Different Hierarchies of Anti–Modified Protein Autoantibody Reactivities in Rheumatoid Arthritis
Arthritis & Rheumatology, 2020 Anti–citrullinated protein antibodies (ACPAs) are a hallmark of seropositive rheumatoid arthritis (RA). Yet, the precise disease‐relevant autoantigens that are targeted by ACPAs remains a matter of debate.
P. Sahlström +15 more
semanticscholar +1 more source
Diabetes Care, 2020 OBJECTIVE The first-appearing β-cell autoantibody has been shown to influence risk of type 1 diabetes (T1D). Here, we assessed the risk of autoantibody spreading to the second-appearing autoantibody and further progression to clinical disease in The ...
Kendra Vehik +12 more
semanticscholar +1 more source
Cell Reports, 2015 Immunoglobulin G (IgG) antibodies are major drivers of autoimmune pathology, but they are also used in the form of intravenous IgG (IVIg) therapy to suppress autoantibody activity. To identify the pathways underlying human autoantibody and IVIg activity,
Inessa Schwab, Anja Lux, Falk Nimmerjahn
doaj +1 more source